Anticancer Drug Development Guide (Cancer Drug Discovery and Development) [Hardcover]

Beverly A. Teicher (Editor), Paul A. Andrews (Editor)

Book Description

Publication Date: February 1, 2004 | ISBN-10: 1588292282 | ISBN-13: 978-1588292285 | Edition: 1

This thoroughly updated and expanded second edition of Beverly Teicher's widely used classic survey provides a step-by-step guide to anticancer drug development from initial design through FDA approval. The authors have included new material on the use of high throughput screening in industry, on specialized in vitro/in vivo procedures employed by the National Cancer Institute (NCI) in preclinical drug evaluations, and on nonclinical testing to support both human clinical trials, as well as trials of biologic oncology products. The chapters on phase I, II, and III clinical trials and on novel phase II clinical trial designs for targeted therapies have been significantly updated, along with those on cancer drug development in Europe, working with the NCI, and the FDA's role in cancer drug development and setting requirements for approval.

Editorial Reviews

Review

From Reviews of the First Edition:

"...traces the critically important pathway by which a 'molecule' becomes an 'an anticancer agent'."
-Unlisted Drugs

"...this book is a must for all oncology fellows and junior faculty interested in drug development and will be a welcome addition on the bookshelf of all oncologists, pharmacists and other professionals interested in understanding this complex area." -Journal of Clinical Oncology

From the Back Cover

In this thoroughly updated and expanded second edition of Beverly Teicher's widely used classic survey, Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, leading cancer researchers from pharmaceutical companies, government laboratories, and academia provide a step-by-step guide to anticancer drug development from initial design through FDA approval. The authors have included new material on the use of high-throughput screening in industry, on specialized in vitro/in vivo procedures employed by the National Cancer Institute (NCI) in preclinical drug evaluations, and on nonclinical testing to support both human clinical trials, as well as trials of biologic oncology products. There are also new chapters on health-related quality of life (HRQL) issues in cancer clinical trials, and FDA review and requirements for approval of oncologic products. The chapters on phase I, II, and III clinical trials and on novel phase II clinical trial designs for targeted therapies have been significantly updated, along with those on cancer drug development in Europe, on working with the NCI, as well as on the FDA's role in cancer drug development and in setting requirements for approval.
Authoritative and up-to-date, Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval takes oncologists, pharmacologists, medicinal chemists, and other cancer researchers on an encyclopedic tour of the cancer drug development and approval process, moving from the design and execution of high-throughput screens, to preclinical testing, to safety and toxicity testing under FDA requirements, to early clinical trials, and on to final FDA approval.

Product Details

• Hardcover: 430 pages
• Publisher: Humana Press; 1 edition (February 1, 2004)
• Language: English
• ISBN-10: 1588292282
• ISBN-13: 978-1588292285
• Product Dimensions: 10.1 x 7.3 x 1.3 inches
• Shipping Weight: 2.5 pounds (View shipping rates and policies)
• Amazon Best Sellers Rank: #464,880 in Books (See Top 100 in Books)
  • #45 in Books > Medical Books > Nursing > Oncology